{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8607.379","value":"30061.30"},{"groupId":"OG001","spread":"9091.460","value":"31299.61"}]}],"title":"Baseline (n:197, 193)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6793.409","value":"22691.18"},{"groupId":"OG001","spread":"8447.992","value":"30223.21"}]}],"title":"Cycle 2 Day 1 (n: 185, 183)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6393.414","value":"22021.23"},{"groupId":"OG001","spread":"8408.405","value":"29264.67"}]}],"title":"Cycle 3 Day 1 (n: 185, 173)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6249.977","value":"21218.17"},{"groupId":"OG001","spread":"8477.049","value":"28308.58"}]}],"title":"Cycle 4 Day 1 (n: 172, 158)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"207"},{"groupId":"OG001","value":"203"}],"units":"Participants"}],"description":"This biomarker is related to angiogenesis pathway, was analyzed to determine the effects of everolimus on plasma antiangiogenic molecules.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 10 mg per day of everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).","id":"OG000","title":"Everolimus 10 mg/Day"},{"description":"Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"The Full Analysis Set (FAS) consists of all patients who were randomized.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1","title":"Plasma Angiogenesis Marker: Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR2)","type":"SECONDARY","unitOfMeasure":"pg/mL"}